Immuno-oncology effectiveness in medicare population is the subject of a study of 20,000 Medicare patients published in JAMA.
Immuno-oncology effectiveness in the Medicare population is the subject of a recently published study. Findings from HDAI and Dana-Farber Cancer Institute Real-world Evidence Study of 20,000 Medicare Patients Shows Shorter Survival Times than Observed in Clinical Trials
Health Data Analytics Institute (HDAI) – an innovator in healthcare AI solutions – and researchers at Dana-Farber Cancer Institute today announced publication of findings exploring the effectiveness of immune checkpoint inhibition for the treatment of Medicare patients with lung cancer. The study, titled “Association between first-line immune checkpoint inhibition and survival for Medicare patients with advanced non-small cell lung cancer,” is posted in the Journal of the American Medical Association (JAMA) Network Open.
About Immuno-oncology Effectiveness in Medicare Population
Immunotherapy is now a cornerstone of treatment for advanced non-small cell lung cancer (NSCLC), but its uptake and effectiveness among older patients outside of clinical trials remains poorly understood. In partnership with Dana-Farber, HDAI conducted a large, real-world evidence study of nearly 20,000 Medicare patients, age 66-89, receiving first line treatment of advanced NSCLC with either immunotherapy, chemotherapy, or a combination of both. The study looked at risk-adjusted restricted mean survival times from patients treated in 2016-2018, with survival follow-up continuing through March 31, 2020.
The median overall survival was 11.4 months among patients receiving immunotherapy alone, which is about 15 months less than reported in a prior clinical trial. The adjusted restricted mean survival time through 18 months of follow-up was 11-13 months for all treatment groups, including those receiving chemotherapy alone.